Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

493
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
493
Cancer-Critical Genes II: Tumor Suppressor Genes01:05

Cancer-Critical Genes II: Tumor Suppressor Genes

7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Immunogenic Cell Death-related Genes Predict Prognosis And Response To Immunotherapy In Lung Squamous Cell Carcinoma

Immunogenic cell death-related genes predict prognosis and response to immunotherapy in lung squamous cell carcinoma

Guoping Li1,2, Kai Chen1,2, Shunli Dong1,2

  • 1Department of Respiratory Medicine, Huzhou Central Hospital, Huzhou, Zhejiang, China.

Biotechnology and Applied Biochemistry
|August 21, 2024

Related Experiment Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

7.5K

View abstract on PubMed

Summary
This summary is machine-generated.

Immunogenic cell death (ICD) classification in lung squamous cell carcinoma (LUSC) predicts patient prognosis and response to immunotherapy. An ICD-based model using CD4, NLRP3, NT5E, and TLR4 genes shows potential for guiding LUSC treatment strategies.

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Lung squamous cell carcinoma (LUSC) presents limited therapeutic avenues.
  • Immunogenic cell death (ICD) can enhance cancer therapy efficacy by stimulating immune responses.
  • Predicting prognosis and immunotherapy response in LUSC is crucial for treatment optimization.

Purpose of the Study:

  • To investigate the utility of ICD-based classification for predicting prognosis in LUSC.
  • To explore the association between ICD subtypes and response to immunotherapy in LUSC patients.
  • To develop an ICD-related risk signature for LUSC.

Main Methods:

  • Consensus clustering of ICD-related gene expression in TCGA LUSC dataset.
  • Differential gene expression analysis, mutation burden, immune cell infiltration, and survival analyses between ICD subtypes.
Keywords:
immunogenic cell deathimmunotherapylung squamous cell carcinomaprognosis

Related Experiment Videos

Predictive Immune Modeling of Solid Tumors
08:50

Predictive Immune Modeling of Solid Tumors

Published on: February 25, 2020

6.9K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K
Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal
08:00

Analyzing Tumor Gene Expression Factors with the CorExplorer Web Portal

Published on: October 11, 2019

7.5K
  • Construction and validation of an ICD-related risk model using key genes (CD4, NLRP3, NT5E, TLR4).

    • Main Results:

    • Two distinct ICD subtypes (ICD-high and ICD-low) were identified, with 1466 differentially expressed genes.
    • The ICD-low group showed a better prognosis, higher TTN/MUC16 mutation rates, increased immune cell infiltration, and lower immune checkpoint expression.
    • An ICD-related model based on CD4, NLRP3, NT5E, and TLR4 accurately predicted LUSC prognosis, with lower risk scores in immunotherapy responders.

    Conclusions:

    • ICD-related gene expression patterns can effectively classify LUSC and predict patient outcomes.
    • The developed ICD risk signature and specific genes (CD4, NLRP3, NT5E, TLR4) show promise for forecasting immunotherapy response in LUSC.
    • This study provides a foundation for leveraging ICD-based strategies to improve immunotherapy efficacy in LUSC patients.
    risk score